#42 - Avrum Bluming, M.D., and Carol Tavris, Ph.D.: Controversial topic affecting all women—the role of hormone replacement therapy through menopause and beyond—the compelling case for long-term HRT and dispelling the myth that it causes breast cancer

Episode Summary

Executive Summary: Peter Attia interviews Carol Tavris and Avram Bluming about their book Estrogen Matters, arguing that menopausal hormone therapy has been unfairly demonized since the Women’s Health Initiative. They contend the evidence supports benefits for many women—especially for symptoms, bone, heart, and brain health—while risks are smaller and more nuanced than commonly believed.

Main Topics: Why the podcast avoids ads and uses subscriber support (Priority: 3/5): Attia explains the show’s funding model: no ads, to preserve trust and avoid conflicts, with members receiving extra content and discounts. Origins of estrogen therapy and historical mistreatment of women (Priority: 5/5): Bluming and Tavris trace how women were overtreated, undertreated, and often harmed by simplistic assumptions about female hormones, including radical surgeries and the 'Feminine Forever' era. Critique of the Women’s Health Initiative (WHI) (Priority: 5/5): The guests argue WHI was biased by older, less healthy participants, excluded symptomatic women, and was communicated in a way that exaggerated harms before full publication. Relative vs absolute risk in hormone therapy (Priority: 5/5): A major theme is that the reported breast cancer risk increase was small in absolute terms and often misunderstood because relative risk was emphasized in media coverage. Benefits of hormone therapy across major outcomes (Priority: 5/5): They discuss evidence that estrogen may reduce menopausal symptoms, osteoporosis/hip fracture, colon cancer, cardiovascular disease, and possibly Alzheimer’s risk. Risks, timing, and patient selection (Priority: 4/5): The conversation emphasizes that risk depends on age, time since menopause, cardiovascular status, and formulation; starting near menopause appears safer than starting late. Hormone therapy after breast cancer (Priority: 4/5): They review evidence suggesting HRT after breast cancer is not clearly associated with recurrence in most studies, though this remains controversial and individualized.

Key Arguments: The WHI’s headline findings were overstated; the initial breast cancer signal was not statistically significant and was later shown to disappear with follow-up. Absolute risk matters more than relative risk: even the reported breast cancer increase translated to a very small number of additional cases per 1,000 women. Estrogen alone did not show the same breast cancer signal as estrogen plus progestin; the apparent combination risk may have been driven by control-group artifacts and prior hormone use. Women were excluded from WHI if they were highly symptomatic, so the trial underrepresented the very people most likely to benefit from therapy. Hormone therapy appears most favorable when started near menopause and in women without established cardiovascular disease; late initiation may carry more risk. Estrogen may reduce risk of osteoporosis-related hip fracture, colon cancer, and possibly Alzheimer’s disease, and may improve quality of life substantially. The common advice to use the 'smallest dose for the shortest time' is presented as more tradition than evidence. Bioidentical hormones are not automatically superior; compounded products raise quality-control concerns, while Premarin has the longest safety/efficacy track record. Women with breast cancer who are on hormones at diagnosis may have better prognosis in some datasets, and many studies of HRT after breast cancer show no increased recurrence. The broader lesson is that women deserve individualized risk-benefit counseling rather than blanket prohibition of hormone therapy.

Data Points: WHI cost: About $1 billion - Attia and guests discuss the scale of the Women’s Health Initiative. WHI enrollment age: Average age 63 - Participants were about 10 years past the average age of menopause. WHI obesity prevalence: About 70% overweight or obese - Used to argue the cohort was not representative of healthy midlife women. WHI smoking prevalence: More than half were smokers - Part of the critique that the sample was cardiovascularly unhealthy. Hormone use prevalence in 2002: About 16 million women, or 22% of the age-appropriate U.S. population - Peak use before WHI-related decline. Hormone use prevalence by 2010: Down to 5% - Shows the magnitude of the post-WHI drop in prescribing. Breast cancer relative risk with combined HRT: 26% increase reported initially - The headline WHI finding for estrogen plus progestin. Breast cancer relative risk with estrogen alone: Hazard ratio about 0.79 - Discussed as a non-significant trend toward lower risk. Breast cancer absolute risk increase: About 0.9 cases per 1,000 women (9 per 10,000) - Attia and guests emphasize the small absolute magnitude even if the relative increase were true. Heart disease vs breast cancer mortality: About 7x more likely to die of cardiovascular disease than breast cancer across the lifespan - Used to argue heart disease deserves more attention in women. Menopause symptom duration: Average about 7.5 years - Guests argue symptoms often last far longer than the commonly cited 1–2 years. Alzheimer’s risk reduction with estrogen: About 20% to 50% reduction depending on study - Presented as a potential preventive benefit. Hip fracture mortality: About 21% die within a year after hip fracture - Used to compare fracture burden with breast cancer mortality. Annual hip fracture deaths in women: About 40,000 - Comparable to annual breast cancer deaths in the U.S. Breast cancer deaths in women annually: About 40,000 - Used in the bone-health discussion. Potential survival gain if all women used HRT: Median survival increase of 3.3 years - Cited from a study by Nananda Col and colleagues. Potential premature deaths after HRT decline: About 50,000 women - Phil Sorrell’s estimate of excess deaths from stopping HRT after WHI. Breast cancer cure rate for early disease: About 90% - Bluming contrasts modern breast cancer outcomes with Alzheimer’s outcomes. Breast cancer prognosis on HRT: Lower mortality stage-for-stage in some studies - Discussed as a counterintuitive finding from WHI follow-up and observational data. VTE/PE risk: Increased, but absolute risk small - Acknowledged as one of the clearer harms of hormone therapy. Gallbladder disease: Increased incidence reported - Another recognized adverse effect of hormone therapy.

Pivotal Quotes: "The more you know, the less you fear." — Carol Tavris: Closing sentiment about evidence-based decision-making and reducing fear around hormone therapy. "If all you care about is looking good, feeling good, and living a long time, then take estrogen." — Unnamed hormone-therapy opponent (quoted by Avram Bluming): Used to illustrate how even critics can inadvertently acknowledge the benefits of HRT. "What were they thinking?" — Carol Tavris: Her critique of the WHI publication and the way its findings were communicated.

Implications: Listeners are urged to treat menopausal hormone therapy as a nuanced, individualized decision rather than a blanket taboo. The episode argues for better risk stratification, more honest communication of absolute risk, and renewed attention to women’s heart, brain, and bone health.